LAM 003

Drug Profile

LAM 003

Alternative Names: LAM-003

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Undisclosed
  • Developer LAM Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 30 Nov 2017 Phase-I clinical trials in Acute myeloid leukaemia in USA (PO) (LAM Therapeutics website, Dec 2017)
  • 30 Nov 2017 US FDA clears LAM Therapeutics' IND for LAM 003 for Leukaemia
  • 19 Apr 2017 LAM Therapeutics completes a phase I trial in Undefined indication in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top